ONCS - Dosing underway in OncoSec's COVID-19 vaccine candidate study

OncoSec Medical ([[ONCS]] -0.4%) has dosed first subjects in Phase 1 trial evaluating its COVID-19 vaccine  candidate, CORVax12, that consists of TAVO (interleukin-12 plasmid), OnocSec's cancer immunotherapy candidate, and DNA-encodable stabilized SARS-CoV-2 spike glycoprotein.The 36-healthy volunteer study aims to evaluate the safety and immunogenicity of a DNA plasmid encoding the SARS-CoV-2 spike protein alone or in combination with CORVax12. CORVax12 will be given as a prime dose and a booster dose four weeks apart.Recent preclinical data on CORVax12 presented at the Society for Immunotherapy of Cancer, demonstrated that CORVax12 induced a strong immune response in mouse models by leading to the production of anti-spike IgG antibodies capable of disrupting the receptor-binding domain of the spike protein.Additionally, preliminary preclinical data has demonstrated that CORVax12 administered into tumor tissue not only yields a productive anti-viral response, but also a strong anti-tumor response.

For further details see:

Dosing underway in OncoSec's COVID-19 vaccine candidate study